




TECHNICAL BULLETIN

TEST CHANGE

EFFECTIVE DATE:12/7/2018

Tumor Marker and Hormone Assay Method Change and Parallel Studies

Northwell Health Laboratories is pleased to announce the following methodology updates and reference range changes for tumor marker and hormone analysis. Parallel studies will be performed during December, January and February at no cost to the patients for clinicians to compare their patients tracking with the new assays. Both results will be reported during parallel testing.

Test Name	Current Assay	Future Assay
Adrenalcorticotrophic Hormone Test Code: ACTH	Method: Sequential Immunometric Instrument: Immulite 2000 Reference Range: 5-46 pg/mL	Method: Electrochemiluminescence Instrument: Roche 801 Reference Range: 7.2-63.3 pg/mL
Cancer Antigen 15-3 Test Code: CA15	Method: Chemiluminescent Microparticle Instrument: Abbott Architect Reference Range: <31.3 U/mL	Method: Electrochemiluminescence Instrument: Roche 801 Reference Range: <25.0 U/mL
Cancer Antigen 19-9 Test Code: CA19	Method: Immunoenzymatic Instrument: Tosoh AIA 2000 Reference Range: <41.3 U/mL	Method: Electrochemiluminescence Instrument: Roche 801 Reference Range: <35 U/mL
Cancer Antigen 125 Test Code: CA125	Method: Chemiluminescent Microparticle Instrument: Abbot Architect Reference Range: <34 U/mL	Method: Electrochemiluminescence Instrument: Roche 801 Reference Range: <38 U/mL
Calcitonin Test Code:CALCTN	Method: Competitive Chemiluminescence Instrument: Immulite 2000 Reference Range: <5pg/mL	Method: Electrochemiluminescence Instrument: Roche 801 Reference Range: Male <= 14.3 pg/mL Female <= 7.6 pg/mL

If you have any questions, please contact Client Services at (516) 719-1100.